Jessica M Franklin

List of Publications by Citations

127 papers	3,885 citations	36 h-index	59 g-index
137 ext. papers	5,067 ext. citations	6.7 avg, IF	5.94 L-index

#	Paper	IF	Citations
127	Antidepressant use in pregnancy and the risk of cardiac defects. *New England Journal of Medicine*, **2014**, 370, 2397-407	59.2	222
126	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. *JAMA Internal Medicine*, **2016**, 176, 1826-1833	11.5	177
125	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. *American Journal of Obstetrics and Gynecology*, **2016**, 215, 353.e1-353.e18	6.4	153
124	Metrics for covariate balance in cohort studies of causal effects. *Statistics in Medicine*, **2014**, 33, 1685-99	2.3	145
123	Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. *Medical Care*, **2013**, 51, 789-96	3.1	133
122	Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. *JAMA Internal Medicine*, **2016**, 176, 763-8	11.5	131
121	Statins and congenital malformations: cohort study. *BMJ, The*, **2015**, 350, h1035	5.9	126
120	Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. *Arthritis and Rheumatology*, **2015**, 67, 1577-85	9.5	123
119	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 924-933	6.1	119
118	Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ, The*, **2019**, 367, l5657	5.9	119
117	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. *Circulation*, **2019**, 139, 2822-2830	16.7	116
116	Effect of Reminder Devices on Medication Adherence: The REMIND Randomized Clinical Trial. *JAMA Internal Medicine*, **2017**, 177, 624-631	11.5	103
115	Matching by propensity score in cohort studies with three treatment groups. *Epidemiology*, **2013**, 24, 401-9	3.1	103
114	The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. *Hypertension*, **2013**, 62, 375-81	8.5	78
113	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. *Journal of Bone and Mineral Research*, **2016**, 31, 1536-40	6.3	76
112	Two decades of new drug development for central nervous system disorders. *Nature Reviews Drug Discovery*, **2015**, 14, 815-6	64.1	75
111	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 867-877	6.1	68

110	Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. *Epidemiology*, **2017**, 28, 387-395	3.1	64
109	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. *Computational Statistics and Data Analysis*, **2014**, 72, 219-226	1.6	60
108	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. *BMJ, The*, **2013**, 347, f5416	5.9	52
107	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. *Circulation*, **2021**, 143, 1002-1013	16.7	52
106	Association between trajectories of statin adherence and subsequent cardiovascular events. *Pharmacoepidemiology and Drug Safety*, **2015**, 24, 1105-13	2.6	51
105	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. *Diabetes Care*, **2019**, 42, 2204-2210	14.6	50
104	Changing interactions between physician trainees and the pharmaceutical industry: a national survey. *Journal of General Internal Medicine*, **2013**, 28, 1064-71	4	49
103	Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. *Statistics in Medicine*, **2017**, 36, 1946-1963	2.3	49
102	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. *Arthritis and Rheumatology*, **2017**, 69, 387-397	9.5	46
101	Distributions of industry payments to Massachusetts physicians. *New England Journal of Medicine*, **2013**, 368, 2049-52	59.2	46
100	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. *Diabetes, Obesity and Metabolism*, **2018**, 20, 974-984	6.7	46
99	Observing versus Predicting: Initial Patterns of Filling Predict Long-Term Adherence More Accurately Than High-Dimensional Modeling Techniques. *Health Services Research*, **2016**, 51, 220-39	3.4	43
98	Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. *Journal of Clinical Oncology*, **2018**, 36, 1805-1812	2.2	41
97	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. *American Journal of Obstetrics and Gynecology*, **2015**, 212, 337.e1-14	6.4	40
96	Variations in PatientsTPerceptions and Use of Generic Drugs: Results of a National Survey. *Journal of General Internal Medicine*, **2016**, 31, 609-14	4	40
95	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. *JAMA Network Open*, **2018**, 1, e180826	10.4	40
94	Using Super Learner Prediction Modeling to Improve High-dimensional Propensity Score Estimation. *Epidemiology*, **2018**, 29, 96-106	3.1	38
93	Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey. *JAMA Internal Medicine*, **2016**, 176, 845-7	11.5	37

92 Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. *Epidemiology*, **2017**, 28, 237-248   3.1   36

91 Surgeon case volume and 30-day mortality after carotid endarterectomy among contemporary medicare beneficiaries: before and after national coverage determination for carotid artery stenting. *Stroke*, **2015**, 46, 1288-94   6.7   35

90 PhysiciansTKnowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1516-8   27.4   35

89 Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. *American Journal of Epidemiology*, **2015**, 182, 651-9   3.8   33

88 Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. *JAMA Network Open*, **2019**, 2, e198061   10.4   32

87 Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 817-826   6.1   31

86 Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications: A Cohort Study. *Annals of Internal Medicine*, **2017**, 166, 81-88   8   30

85 Association of marketing interactions with medical traineesTknowledge about evidence-based prescribing: results from a national survey. *JAMA Internal Medicine*, **2014**, 174, 1283-90   11.5   29

84 Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. *BMJ Quality and Safety*, **2013**, 22, 727-34   5.4   25

83 Effects of expanding the look-back period to all available data in the assessment of covariates. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 890-899   2.6   24

82 Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. *Pharmacoepidemiology and Drug Safety*, **2020**, 29, 1228-1235   2.6   24

81 Predicting Adherence to Chronic Disease Medications in Patients with Long-term Initial Medication Fills Using Indicators of Clinical Events and Health Behaviors. *Journal of Managed Care & Specialty Pharmacy*, **2018**, 24, 469-477   1.9   24

80 Implications of the Propensity Score Matching Paradox in Pharmacoepidemiology. *American Journal of Epidemiology*, **2018**, 187, 1951-1961   3.8   24

79 Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. *JAMA Network Open*, **2020**, 3, e2031647   10.4   24

78 Predicting adherence trajectory using initial patterns of medication filling. *American Journal of Managed Care*, **2015**, 21, e537-44   2.1   24

77 Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. *American Journal of Medicine*, **2015**, 128, 539.e7-17   2.4   21

76 Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. *Arthritis Care and Research*, **2013**, 65, 2008-14   4.7   21

75 An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. *PLoS ONE*, **2018**, 13, e0193622   3.7   21

74	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004632	5.8	17
73	Application and impact of run-in studies. *Journal of General Internal Medicine*, **2018**, 33, 759-763	4	16
72	Predicting 1-Year Statin Adherence Among Prevalent Users: A Retrospective Cohort Study. *Journal of Managed Care & Specialty Pharmacy*, **2017**, 23, 494-502	1.9	16
71	Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. *Journal of the American Geriatrics Society*, **2015**, 63, 516-23	5.6	15
70	Scalable collaborative targeted learning for high-dimensional data. *Statistical Methods in Medical Research*, **2019**, 28, 532-554	2.3	15
69	Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. *Statistical Methods in Medical Research*, **2019**, 28, 1044-1063	2.3	15
68	Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies. *Epidemiology*, **2014**, 25, 126-33	3.1	14
67	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. *JACC Basic To Translational Science*, **2016**, 1, 301-308	8.7	14
66	Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. *Journal of General Internal Medicine*, **2019**, 34, 2339-2341	4	13
65	Longitudinal Patterns of Spending Enhance the Ability to Predict Costly Patients: A Novel Approach to Identify Patients for Cost Containment. *Medical Care*, **2017**, 55, 64-73	3.1	13
64	Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data. *American Journal of Epidemiology*, **2020**, 189, 613-622	3.8	13
63	The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. *American Heart Journal*, **2018**, 197, 153-162	4.9	13
62	Propensity score prediction for electronic healthcare databases using Super Learner and High-dimensional Propensity Score Methods. *Journal of Applied Statistics*, **2019**, 46, 2216-2236	1	12
61	Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2029-2038	6.7	11
60	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. *Journal of General Internal Medicine*, **2015**, 30, 1633-8	4	11
59	Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. *Drug Safety*, **2018**, 41, 1333-1342	5.1	11
58	Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. *JAMA - Journal of the American Medical Association*, **2017**, 318, 388-389	27.4	11
57	A Bias in the Evaluation of Bias Comparing Randomized Trials with Nonexperimental Studies. *Epidemiologic Methods*, **2017**, 6,	2.2	11

56	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 36-43	7.3	11
55	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. *American Journal of Epidemiology*, **2019**, 188, 609-616	3.8	11
54	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1513-1521	6.1	10
53	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 146, 472-8	1.5	10
52	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 979-993	6.1	10
51	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 735-737	6.1	9
50	Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. *JAMA Network Open*, **2019**, 2, e197591	10.4	9
49	Medical Schools┐Industry Interaction Policies Not Associated With Trainees┐Self-Reported Behavior as Residents: Results of a National Survey. *Journal of Graduate Medical Education*, **2015**, 7, 595-602	1.6	9
48	Association of medical students┐reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. *PLoS Medicine*, **2014**, 11, e1001743	11.6	9
47	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005173	5.8	7
46	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. *Drug Safety*, **2015**, 38, 1075-82	5.1	7
45	Physicians┐Trust in the FDA┐s Use of Product-Specific Pathways for Generic Drug Approval. *PLoS ONE*, **2016**, 11, e0163339	3.7	7
44	Time to Filling of New Prescriptions for Chronic Disease Medications Among a Cohort of Elderly Patients in the USA. *Journal of General Internal Medicine*, **2018**, 33, 1877-1884	4	7
43	Rationale and design of the Randomized Evaluation to Measure Improvements in Non-adherence from Low-Cost Devices (REMIND) trial. *Contemporary Clinical Trials*, **2015**, 43, 53-9	2.3	6
42	Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. *Pharmacoepidemiology and Drug Safety*, **2014**, 23, 830-8	2.6	6
41	Real-world evidence to support regulatory decision making: New or expanded medical product indications. *Pharmacoepidemiology and Drug Safety*, **2021**, 30, 685-693	2.6	6
40	Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. *Drug Safety*, **2015**, 38, 589-600	5.1	5
39	Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. *American Journal of Epidemiology*, **2017**, 185, 474-478	3.8	5

38	Evaluating Cardiovascular Health Disparities Using Estimated Race/Ethnicity: A Validation Study. *Medical Care*, **2015**, 53, 1050-7	3.1	5
37	Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data. *PLoS ONE*, **2020**, 15, e0241083	3.7	5
36	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. *Epidemiology*, **2020**, 31, 82-89	3.1	5
35	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	5
34	Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. *Pharmacoepidemiology and Drug Safety*, **2016**, 25, 444-52	2.6	5
33	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 694-701	2.6	4
32	Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10,	5.8	4
31	The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change. *Health Policy*, **2017**, 121, 27-34	3.2	4
30	Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. *Medical Decision Making*, **2013**, 33, 949-60	2.5	4
29	How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. *BMJ Open*, **2021**, 11, e043961	3	4
28	Postoperative inpatient utilization of opioid and opioid-sparing analgesics in the United States hospitals, 2007-2017. *Pharmacoepidemiology and Drug Safety*, **2021**, 30, 390-394	2.6	4
27	A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. *EClinicalMedicine*, **2021**, 32, 100730	11.3	4
26	Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. *Journal of General Internal Medicine*, **2018**, 33, 792-794	4	3
25	The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. *Endocrinology, Diabetes and Metabolism*, **2020**, 3, e00103	2.7	3
24	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. *Epidemiology*, **2020**, 31, 806-814	3.1	3
23	Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. *BMJ Open*, **2016**, 6, e011015	3	3
22	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 816-828	6.1	3
21	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. *Hypertension Research*, **2021**, 44, 1471-1482	4.7	3

20	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. *Journal of Comparative Effectiveness Research*, **2017**, 6, 613-625	2.1	2
19	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching-A plasmode simulation study. *Pharmacoepidemiology and Drug Safety*, **2019**, 28, 879-886	2.6	2
18	Physician traineesTinteractions with the pharmaceutical industry. *Journal of General Internal Medicine*, **2013**, 28, 1267	4	2
17	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. *Arthritis Research and Therapy*, **2017**, 19, 130	5.7	2
16	Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. *American Journal of Obstetrics & Gynecology MFM*, **2021**, 3, 100304	7.4	2
15	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. *PLoS ONE*, **2016**, 11, e0152195	3.7	2
14	P-values and decision-making: discussion of TLimitations of empirical calibration of p-values using observational dataT *Statistics in Medicine*, **2016**, 35, 3889-91	2.3	2
13	Response by Franklin and Schneeweiss to Letters Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". *Circulation*, **2021**, 144, e162-e163	16.7	2
12	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 874-884	6.1	1
11	The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. *PLoS ONE*, **2017**, 12, e0175313	3.7	1
10	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. *Pharmacoepidemiology and Drug Safety*, **2018**, 27, 383-390	2.6	1
9	A concept-wide association study to identify potential risk factors for nonadherence among prevalent users of antihypertensives. *Pharmacoepidemiology and Drug Safety*, **2019**, 28, 1299-1308	2.6	1
8	Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis. *Osteoporosis International*, **2014**, 25, 2255-62	5.3	1
7	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 1334-1342	6.1	1
6	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. *Journal of General Internal Medicine*, **2021**, 36, 2601-2607	4	0
5	Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. *Annals of Internal Medicine*, **2017**, 166, 761-762	8	
4	Response to the Comment on Evaluating Cardiovascular Health Disparities Using Estimated Race/Ethnicity: A Validation Study. *Medical Care*, **2016**, 54, 965-6	3.1	
3	Alendronate and Hip Fracture in Patients Using Glucocorticoids. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1711-1712	27.4	

LIST OF PUBLICATIONS

2   Brief discussion on sampling variability in 1:1 propensity score matching without replacement. *Pharmacoepidemiology and Drug Safety*, **2020**, 29, 1194-1197

2.6

1   Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions-Reply. *JAMA Internal Medicine*, **2016**, 176, 1577

11.5